Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP495336.RAWPXc-zaep2OurTnkxP7NJFRP6PWJDf87kaJK-ZaG4xk130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP495336.RAWPXc-zaep2OurTnkxP7NJFRP6PWJDf87kaJK-ZaG4xk130_provenance.
• NP278767.RAJVSZWzVylcs0_l2_AYsFjfd2j0FrhY00iV6nhIhmU2g130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP278767.RAJVSZWzVylcs0_l2_AYsFjfd2j0FrhY00iV6nhIhmU2g130_provenance.
• NP410518.RAYp0Yaf0-AZWfBcBMGKqVYzTkhL4xtrdxgyZbgKwl3sI130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP410518.RAYp0Yaf0-AZWfBcBMGKqVYzTkhL4xtrdxgyZbgKwl3sI130_provenance.
• NP578579.RAQuePikgayp8Op19Ep8YqNZRWoHDyqpRm8IR7gkkNZ70130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP578579.RAQuePikgayp8Op19Ep8YqNZRWoHDyqpRm8IR7gkkNZ70130_provenance.
• NP694531.RA2fZsKDZTY54PbAxKWUW_eUfPFlrO9RqC_3MObbo8lUc130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP694531.RA2fZsKDZTY54PbAxKWUW_eUfPFlrO9RqC_3MObbo8lUc130_provenance.
• NP789622.RAx-itnNMIByuvd2N1g3VnCamAlU_andV4SJxPxWo087U130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP789622.RAx-itnNMIByuvd2N1g3VnCamAlU_andV4SJxPxWo087U130_provenance.
• NP430303.RASEKfAin6bpyBvJys-wktfQMcEnKLL1tDi0J36ogT1jw130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP430303.RASEKfAin6bpyBvJys-wktfQMcEnKLL1tDi0J36ogT1jw130_provenance.
• NP430307.RAYJ8A6b6rajmaZhSRftxPQLaFdgS9klCEUrAidwk8lhQ130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP430307.RAYJ8A6b6rajmaZhSRftxPQLaFdgS9klCEUrAidwk8lhQ130_provenance.
• NP430300.RAmtOatdjskBDKiW46VNAaBkx0g8-7VE3EOcACnVYG-e8130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP430300.RAmtOatdjskBDKiW46VNAaBkx0g8-7VE3EOcACnVYG-e8130_provenance.
• NP430304.RAiKolGChZ932Jhn07pEcK29j40Hoc9vRDRvuIUBprEqg130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP430304.RAiKolGChZ932Jhn07pEcK29j40Hoc9vRDRvuIUBprEqg130_provenance.
• NP430306.RAnqN9xOPmDc_uuabvHiujEb_QteieuIV2Vy7tt-BwL7Y130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP430306.RAnqN9xOPmDc_uuabvHiujEb_QteieuIV2Vy7tt-BwL7Y130_provenance.
• NP410470.RA0Tgo59W_Q2qKrJT5mJq-6pEXE9-r3jV96oDz8vge5jU130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP410470.RA0Tgo59W_Q2qKrJT5mJq-6pEXE9-r3jV96oDz8vge5jU130_provenance.
• NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_provenance.
• NP430302.RA1FCbdI-n7VqRYaj8thNhwGj4xkahku-5uPpiVaaTJwo130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP430302.RA1FCbdI-n7VqRYaj8thNhwGj4xkahku-5uPpiVaaTJwo130_provenance.
• NP430305.RA6K3QGHMglNKA2EgqzEkxVPSQXpW-8GLiRDIa6o7g7JI130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP430305.RA6K3QGHMglNKA2EgqzEkxVPSQXpW-8GLiRDIa6o7g7JI130_provenance.